Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

5 Apr 2018 14:08

RNS Number : 9965J
Diurnal Group PLC
05 April 2018
 

5 April 2018

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Director Dealings

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following Directors' share sale and re-purchase transactions, undertaken for tax planning purposes:

 

Peter Allen, Chairman, today sold 10,000 ordinary shares of 5 pence each in Diurnal Group plc ("Ordinary Shares") at a price of 202 pence per Ordinary Share and his SIPP purchased 10,000 Ordinary Shares at a price of 202 pence per Ordinary Share. Following the transactions, Peter Allen's total beneficial interest remains unchanged at 84,722 Ordinary Shares, representing 0.14% of the total voting rights.

 

Sam Williams, Non-executive Director, today sold 5,500 Ordinary Shares at a price of 199 pence per Ordinary Share and his ISA purchased 5,500 Ordinary Shares at a price of 199 pence per Ordinary Share. Following the transactions, Sam Williams' total beneficial interest remains unchanged at 52,248 Ordinary Shares, representing 0.09% of the total voting rights.

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer

Richard Bungay, Chief Financial Officer

Numis Securities Ltd (Nominated Adviser)

+44 (0)20 7260 1000

Nominated Adviser: Michael Meade, Paul Gillam, Freddie Barnfield

Corporate Broking: James Black

Panmure Gordon (UK) Limited (Joint Broker)

+44 (0) 20 7886 2500

Corporate Finance: Freddy Crossley

Corporate Broking: Tom Salvesen

FTI Consulting

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

 

 

Notes to Editors

 

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Peter Allen

2

 

Reason for the notification

 

a)

 

Position/status

 

Chairman

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each in Diurnal Group plc

Identification code

GB00BDB6Q760

b)

 

Nature of the transaction

 

Sale

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

202p

10,000

d)

 

Aggregated information

- Aggregated volume

N/A - single transaction

- Price

e)

 

Date of the transaction

 

5 April 2018

f)

 

Place of the transaction

 

XLON

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Peter Allen

2

 

Reason for the notification

 

a)

 

Position/status

 

Chairman

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each in Diurnal Group plc

Identification code

GB00BDB6Q760

b)

 

Nature of the transaction

 

Purchase

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

202p

10,000

d)

 

Aggregated information

- Aggregated volume

N/A - single transaction

- Price

e)

 

Date of the transaction

 

5 April 2018

f)

 

Place of the transaction

 

XLON

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Sam Williams

2

 

Reason for the notification

 

a)

 

Position/status

 

Non-executive Director

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each in Diurnal Group plc

Identification code

GB00BDB6Q760

b)

 

Nature of the transaction

 

Sale

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

199p

5,500

d)

 

Aggregated information

- Aggregated volume

N/A - single transaction

- Price

e)

 

Date of the transaction

 

5 April 2018

f)

 

Place of the transaction

 

XLON

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Sam Williams

2

 

Reason for the notification

 

a)

 

Position/status

 

Non-executive Director

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each in Diurnal Group plc

Identification code

GB00BDB6Q760

b)

 

Nature of the transaction

 

Purchase

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

199p

5,500

d)

 

Aggregated information

- Aggregated volume

N/A - single transaction

- Price

e)

 

Date of the transaction

 

5 April 2018

f)

 

Place of the transaction

 

XLON

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHSSIFDIFASESL
Date   Source Headline
7th Sep 202212:00 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
7th Sep 20229:58 amRNSForm 8.5 (EPT/RI)
7th Sep 20229:23 amRNSMole Valley Asset Management Ltd-Form 8.3 Diurnal
6th Sep 20221:36 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
6th Sep 202212:00 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
6th Sep 20229:04 amRNSForm 8.3 - [DIURNAL GROUP PLC]
5th Sep 20223:16 pmRNSForm 8.3 - Diurnal Group Plc
5th Sep 20221:36 pmRNSForm 8 (OPD) (Diurnal Group)
5th Sep 202212:00 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
2nd Sep 20224:28 pmRNSForm 8 (OPD) (Neurocrine Biosciences, Inc.)
2nd Sep 20222:55 pmRNSForm 8.3 - Diurnal Group plc
2nd Sep 202212:00 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
2nd Sep 20228:58 amRNSForm 8.5 (EPT/RI)
1st Sep 20223:12 pmRNSForm 8.3 - Diurnal Group plc
1st Sep 20221:20 pmRNSForm 8.3 - Diurnal Group Plc
1st Sep 202212:00 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
1st Sep 202210:04 amRNSForm 8.5 (EPT/RI)
1st Sep 20229:38 amRNSForm 8.3 - [DIURNAL GROUP PLC]
1st Sep 20227:00 amRNSPostponement of R&D Day and Notice of Results
31st Aug 20223:20 pmRNSForm 8.3 - Diurnal Group plc
31st Aug 20222:03 pmRNSForm 8.3 - Diurnal Group PLC
31st Aug 202212:53 pmRNSForm 8.3 DIURNAL GROUP PLC
31st Aug 202212:00 pmRNSForm 8.5 (EPT/RI) - Diurnal Group plc
31st Aug 202211:56 amRNSForm 8.5 (EPT/RI) - Diurnal Group PLC
31st Aug 202211:55 amRNSForm 8.3 - Diurnal Group plc
31st Aug 202211:46 amGNWForm 8.3 - [Diurnal Group plc - 30 08 2022 - Opening Declaration] - (HHL)
31st Aug 20229:08 amRNSForm 8.3 - Diurnal Group PLC
30th Aug 202212:55 pmRNSForm 8.3 - DIURNAL GROUP PLC
30th Aug 202212:32 pmEQSForm 8.3 - Maitland Institutional Services Limited: Re Diurnal Group plc
30th Aug 20227:00 amRNSRECOMMENDED CASH ACQUISITION
26th Jul 20227:00 amRNSTrading Update
15th Jul 202212:04 pmRNSDirector Dealings
30th Jun 20221:29 pmRNSBlock Listing Six Monthly Return
7th Jun 20221:00 pmRNSDiurnal to present research at ENDO 2022
1st Jun 20227:00 amRNSFirst patient dosed in pivotal Phase 3 trial
23rd May 20228:41 amRNSCorrection: Presentation at ECE
23rd May 20227:00 amRNSPresentation at European Congress of Endocrinology
9th May 202212:49 pmRNSDirector Dealings
29th Apr 20223:37 pmRNSTotal Voting Rights
28th Apr 20227:00 amRNSDiurnal to present at Investor Evening
25th Apr 20227:00 amRNSDistribution agreement signed with EffRx
20th Apr 20227:00 amRNSDistribution agreement signed with Er-Kim
4th Apr 20227:00 amRNSDirectorate Change and Management Updates
1st Apr 20227:00 amRNSTotal Voting Rights
30th Mar 20227:00 amRNSDistribution agreement with Vector Pharma
22nd Mar 20224:35 pmRNSPrice Monitoring Extension
22nd Mar 20222:06 pmRNSSecond Price Monitoring Extn
22nd Mar 20222:00 pmRNSPrice Monitoring Extension
22nd Mar 20227:00 amRNSInterim Results
9th Mar 20227:00 amRNSInterim Results Investor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.